BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.90
+0.03 (0.38%)
Jan 31, 2025, 4:00 PM EST - Market closed
BioCryst Pharmaceuticals Revenue
BioCryst Pharmaceuticals had revenue of $117.09M in the quarter ending September 30, 2024, with 34.98% growth. This brings the company's revenue in the last twelve months to $412.58M, up 29.92% year-over-year. In the year 2023, BioCryst Pharmaceuticals had annual revenue of $331.41M with 22.37% growth.
Revenue (ttm)
$412.58M
Revenue Growth
+29.92%
P/S Ratio
3.93
Revenue / Employee
$769,737
Employees
536
Market Cap
1.64B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | 48.84M | 28.18M | 136.45% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
BCRX News
- 22 days ago - BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - GlobeNewsWire
- 25 days ago - BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 26 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy - Seeking Alpha
- 2 months ago - BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewsWire
- 3 months ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioCryst to Report Third Quarter 2024 Financial Results on November 4 - GlobeNewsWire